Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (NASDAQ: IRIX) has secured a strategic investment of $10 million from Novel Inspiration International Co., , with an option for an additional $10 million for future growth initiatives. The initial transaction includes $6 million in new Series B Preferred Stock and $4 million in convertible notes, both priced at $2.00 per share equivalent.
The convertible notes have a three-year term with 12% interest, payable quarterly in common stock. Novel has the right to appoint two board members, with William Moore, former CEO and board member, joining the board. The funding will be used to repay existing debt and for general corporate purposes.
The company also announced the appointment of Romeo Dizon as CFO, replacing Interim CFO Fuad Ahmad. This strategic investment aims to enhance Iridex's ability to pursue opportunities in advanced laser-based treatments, particularly following the November 2024 LCD that introduced new limitations for MIGS devices.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has addressed recent stock price volatility observed on March 13, 2025. The company explicitly stated there are no material developments or changes to its operating or financial condition that would explain the recent price and volume movements.
The company confirmed that no material adverse changes have occurred to its operating results, business, strategy, or prospects since their preliminary Q4 and full year 2024 results announcement on January 14, 2025. Final financial results will be discussed during a conference call scheduled for March 27, 2025, at 2:00pm PT.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 (Conference ID: 5685253) or access the webcast through the Event Calendar on Iridex's investor relations website.
Iridex (IRIX) has released preliminary Q4 and full-year 2024 results. Q4 revenue is expected between $12.6-12.7 million, slightly up from $12.5 million in Q4 2023. The company maintained stable Cyclo G6® probe sales at 12,700 units and increased Cyclo G6 Glaucoma Laser Systems sales to 47 units from 35 year-over-year.
Full-year 2024 revenue is projected at $48.6-48.7 million, down from $51.9 million in 2023. Annual Cyclo G6® probe sales decreased to 54,800 from 55,200, while Glaucoma Laser Systems sales declined to 125 from 164 units. The company reports progress in cost restructuring initiatives and achieving positive EBITDA in Q4 2024. A strategic review process with multiple parties remains ongoing.
Iridex (IRIX) announced a landmark five-year peer-reviewed study published in Ophthalmology Therapy, demonstrating the long-term effectiveness of their MicroPulse Transscleral Laser Therapy (TLT) for glaucoma treatment. The study, conducted at University Eye Clinic Maastricht, evaluated 165 eyes with 112 completing the five-year follow-up.
Key findings showed significant results using the Cyclo G6® Laser and MicroPulse P3® Delivery Device: a 32.5% average reduction in intraocular pressure (IOP), decreased need for IOP-lowering medications, and only 38% of eyes requiring retreatment. The study confirms TLT as a viable alternative to invasive surgery, with sustained effectiveness and minimal complications across various glaucoma types.
Iridex (Nasdaq: IRIX) confirms the adoption of Local Coverage Determination (LCD) L37531 for Micro-Invasive Glaucoma Surgery (MIGS), effective November 17, 2024. The new LCD clarifies that Iridex's laser-based treatments are not MIGS procedures and remain unaffected by new reimbursement limitations. The company's Cyclo G6® product family, which currently sells over 50,000 probes annually, offers noninvasive, repeatable treatments across various stages of glaucoma progression. The LCD's restrictions on MIGS procedures are expected to increase physician interest in Iridex's laser-based alternatives.
Iridex reported its third quarter 2024 financial results, showing a total revenue of $11.6 million, a sequential decline of 8% from Q2 2024 and a 10% decline from Q3 2023. The Cyclo G6 product family generated $3.1 million in revenue, a 3% increase from Q3 2023. However, retina product revenue fell to $6.5 million, a 12% sequential decline and an 18% drop year-over-year. The company strengthened its balance sheet with $3.4 million in net proceeds from a convertible note offering. Cash and cash equivalents were approximately $3.9 million as of September 28, 2024.
Iridex expects to achieve EBITDA breakeven in Q4 2024 due to cost-cutting measures. The company also announced new Local Coverage Determinations (LCDs) for Medicare reimbursement, effective November 17, 2024, which could boost the use of its glaucoma products. The company is undergoing a strategic review and is in discussions with multiple parties regarding potential transactions.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its third quarter 2024 financial results release for November 12, 2024, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone (1-888-596-4144 for domestic, +1-646-968-2525 for international callers, conference ID: 3650755) or through a webcast available on the company's website.
Iridex (Nasdaq: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has announced significant leadership changes. Patrick Mercer, previously the company's Chief Operating Officer and President, has been appointed as the new Chief Executive Officer and President, effective October 1, 2024. This change comes as David Bruce, the former CEO, transitions out of the company.
Simultaneously, Scott Shuda has been named Executive Chairman of the board of directors, upgrading from his previous role as Chairman. The board believes these leadership changes could accelerate progress towards a potential transaction, as part of the strategic review process announced last year. Iridex continues to engage in discussions with multiple entities regarding potential transactions.
Mr. Mercer expressed his commitment to advancing Iridex's mission and highlighted the company's value as a global leader in ophthalmic laser treatment systems, featuring technologies like the Next Gen Pascal® with MicroPulse® for retina and MicroPulse Transscleral Laser Therapy for glaucoma.
Iridex (Nasdaq: IRIX) announced its Q2 2024 financial results. The company reported total revenue of $12.6 million, marking a 7% sequential growth from Q1 2024. The Cyclo G6 product family revenue increased by 13% sequentially to $3.3 million. Retina product revenue grew 8% sequentially and 6% YoY to $7.3 million. The company sold 15,100 Cyclo G6 probes and 28 Glaucoma Laser Systems.
Gross profit was $5.1 million with a 40.7% margin, down from 41.7% YoY. Net loss stood at $2.7 million, or $0.16 per share. Operating expenses decreased to $7.8 million. Cash and equivalents were $4.1 million as of June 29, 2024, reduced by $1.3 million in the quarter, and excluding $3.4 million from a convertible note offering on August 7, 2024.
CEO David Bruce emphasized the company's focus on strategic review processes and achieving a transaction this fiscal year. A webcast and conference call were scheduled to discuss these results.